Lanifibranor (IVA-337)

Why It Matters

MASH affects millions and lacks approved disease‑modifying drugs; a successful pan‑PPAR agent could reshape the therapeutic landscape and capture a multibillion‑dollar market.

Key Takeaways

• Oral pan‑PPAR agonist targeting MASH/MASLD
• Phase 3 trial underway, results pending
• Developed by Inventiva Pharma, optimized from HTS
• Published data in Journal of Hepatology, June 2025
• Potential first pan‑PPAR therapy for liver disease

Pulse Analysis

Metabolic dysfunction‑associated steatohepatitis, formerly known as NASH, has emerged as a leading cause of chronic liver failure worldwide. With prevalence rates climbing alongside obesity and type‑2 diabetes, the condition drives a multi‑billion‑dollar market yet remains without an approved disease‑modifying therapy. Peroxisome proliferator‑activated receptors (PPARs) regulate lipid metabolism, inflammation, and fibrogenesis, making them attractive targets for halting MASH progression. While selective PPAR‑α or PPAR‑γ agonists have shown modest benefits, a pan‑PPAR approach promises broader metabolic rebalancing.

Lanifibranor (IVA‑337) embodies this strategy as an oral pan‑PPAR agonist that simultaneously engages all three isoforms. Inventiva Pharma refined the molecule from an initial high‑throughput screen, improving potency and safety before advancing to clinical evaluation. The Phase 3 trial, launched after promising Phase 2 data published in the Journal of Hepatology (June 2025), enrolls patients with biopsy‑proven MASH and targets key endpoints: resolution of steatohepatitis without worsening fibrosis and at least one‑stage fibrosis regression. By addressing both inflammatory and fibrotic pathways, lanifibranor aims to deliver the first comprehensive histologic improvement in this disease.

If the Phase 3 outcomes meet regulatory expectations, lanifibranor could become the inaugural pan‑PPAR therapy approved for MASH, setting a new standard of care. Its success would pressure competitors to pursue multi‑isoform PPAR modulation or combination regimens, potentially accelerating innovation across the hepatology pipeline. Moreover, a positive readout would bolster investor confidence in liver‑focused biotech firms, catalyzing further capital inflow into the space and expanding treatment options for the growing patient population.